UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN-LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION

Mirjana Andjelkovic; Danielle Abi-Saab; Paul Delmar; Nathalie Pross; Nicola Voyle; Gregory Klein; Michaela Mertes; Smiljana Ristic; Ferenc Martenyi; Paulo Fontoura; Rachelle Doody

首页> 外文期刊>Alzheimer’s & dementia: the journal of the Alzheimer’s Association >UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN-LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION

【24h】

UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN-LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION

机译：在大约2年后的研究持续时间后，对夏季公路研究的古老公路研究中甘蓝型研究延长的安全性和耐受性的更新

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Alzheimer’s & dementia: the journal of the Alzheimer’s Association》 |2018年第7期|共2页
作者
Mirjana Andjelkovic; Danielle Abi-Saab; Paul Delmar; Nathalie Pross; Nicola Voyle; Gregory Klein; Michaela Mertes; Smiljana Ristic; Ferenc Martenyi; Paulo Fontoura; Rachelle Doody;
展开▼
作者单位

F. Hoffmann-La Roche Ltd;

F. Hoffmann-La Roche Ltd;

F. Hoffmann-La Roche Ltd;

F. Hoffmann-La Roche Ltd;

Roche Products Ltd;

F. Hoffmann-La Roche Ltd;

F. Hoffmann-La Roche Ltd;

F. Hoffmann-La Roche Ltd;

F. Hoffmann-La Roche Ltd;

F. Hoffmann-La Roche Ltd;

Product Development Neuroscience F. Hoffmann-La Roche Ltd;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN-LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION [J] . Mirjana Andjelkovic, Danielle Abi-Saab, Paul Delmar, Alzheimer’s & dementia: the journal of the Alzheimer’s Association . 2018,第7期

机译：在大约2年后的研究持续时间后，对夏季公路研究的古老公路研究中甘蓝型研究延长的安全性和耐受性的更新
2. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease [J] . Farlow Martin R., Grossberg George T., Sadowsky Carl H., Alzheimer disease and associated disorders . 2015,第2期

机译：一项为期24周的开放标签扩展研究，用于研究重度阿尔茨海默氏病患者中13.3 mg / 24 h Rivastigmine贴剂的长期安全性，耐受性和功效
3. Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study [J] . Rikkert Marcel G. M. Olde, Verhey Frans R., Blesa Rafael, Journal of Alzheimer's disease: JAD . 2015,第2期

机译：Souvenaid在轻度阿尔茨海默氏病患者中的耐受性和安全性：多中心，24周，开放标签扩展研究的结果
4. Hippocampus morphometry study on pathology-confirmed Alzheimer's disease patients with surface multivariate morphometry statistics [C] . Jianfeng Wu, Jie Zhang, Jie Shi, IEEE International Symposium on Biomedical Imaging . 2018

机译：海马形态计量学在病理证实的阿尔茨海默氏病患者中的研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Long-Term Safety and Tolerability of Rivastigmine in Patients With Alzheimers Disease Switched From Donepezil: An Open-Label Extension Study [O] . Gary S. Figiel, Barbara Koumaras, Xiangyi Meng, 2008

机译：从多奈哌齐治疗阿尔茨海默氏病患者中利伐斯的明的长期安全性和耐受性：一项开放标签扩展研究
7. A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease [O] . B. Leavitt, S. Tabrizi, P. Sanwald Ducray, 2019

机译：来自早期攀登亨廷顿疾病的成人RG6042的持续开放标签扩展研究的安全，耐受性和生物标志物更新

UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN-LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION

著录项

相似文献

相关主题

期刊订阅